Directorate Change (9960M)

TIDMHIK

RNS Number : 9960M

Hikma Pharmaceuticals Plc

25 August 2011

Hikma Appoints Robert Pickering, former CEO of Cazenove PLC, to the Board

London, 25 August 2011 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ("Hikma"), the FTSE 250 pharmaceuticals company, announces the appointment of Mr. Robert Pickering as an independent non-executive director of the Company with effect from 1 September 2011.

Commenting on the appointment, Samih Darwazah, Hikma's Chairman said, "I am delighted to welcome an individual of Robert's high calibre and experience to the Board. He is an excellent addition with extensive experience in advising high growth companies on issues relating to corporate governance, strategy and global operations."

Robert Pickering said, "Hikma has a long and impressive track record and has strong growth prospects from its positions in the MENA markets and internationally. Hikma is also respected for quality and integrity across all its operations and I look forward to joining the Board."

Mr Pickering will join the Board's Audit and Remuneration Committees, as well as the Compliance, Responsibility and Ethics Committee.

Mr Pickering spent 23 years at Cazenove & Co. becoming the first Chief Executive of Cazenove Group PLC in 2001. He served as Chief Executive of Cazenove and also JP Morgan Cazenove, the joint venture partnership, until his retirement in 2008. He has extensive experience of capital raising, mergers and acquisitions and of the relationship between quoted companies and investors. Robert is a qualified solicitor with a law degree from Lincoln College, Oxford. He is a non-executive director of Neptune Asset Management.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760

Financial Dynamics +44 (0)20 7831 3113

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).

Regulatory

There are no other details in respect of this appointment that are relevant to be disclosed pursuant to the Listing Rules of the Financial Services Authority or the Offered Securities Rules of the Dubai Financial Services Authority. Mr Pickering's appointment was made with the assistance of external recruitment consultants.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAPGUPGRUPGGRC

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024